Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)—study protocol

Azuara-Blanco, Augusto, Logan, Nicola, Strang, Niall, Saunders, Kathryn, Allen, Peter M, Weir, Ruth, Doherty, Paul, Adams, Catherine, Gardner, Evie, Hogg, Ruth, McFarland, Margaret, Preston, Jennifer, Verghis, Rejina, Loughman, James J, Flitcroft, Ian, Mackey, David A, Lee, Samantha Sze-Yee, Hammond, Christopher, Congdon, Nathan and Clarke, Mike (2019). Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)—study protocol. British Journal of Ophthalmology ,

Abstract

Background/aims: To report the protocol of a trial designed to evaluate the efficacy, safety and mechanism of action of low-dose atropine (0.01%) eye-drops for reducing progression of myopia in UK children. Methods: Multicentre, double-masked, superiority, placebo-controlled, randomised trial. We will enrol children aged 6-12 years with myopia of -0.50 dioptres or worse in both eyes. We will recruit 289 participants with an allocation ratio of 2:1 (193 atropine; 96 placebo) from five centres. Participants will instil one drop in each eye every day for 2 years and attend a research centre every 6 months. The vehicle and preservative will be the same in both study arms. The primary outcome is SER of both eyes measured by autorefractor under cycloplegia at 2 years (adjusted for baseline). Secondary outcomes include axial length, best corrected distance visual acuity, near visual acuity, reading speed, pupil diameter, accommodation, adverse event rates and allergic reactions, quality of life (EQ-5D-Y) and tolerability at 2 years. Mechanistic evaluations will include: peripheral axial length, peripheral retinal defocus, anterior chamber depth, iris colour, height and weight, activities questionnaire, ciliary body biometry and chorioretinal thickness. Endpoints from both eyes will be pooled in combined analysis using generalised estimating equations to allow for the correlation between eyes within participant. Three years after cessation of treatment, we will also evaluate refractive error and adverse events. Conclusions: The Childhood Atropine for Myopia Progression in the UK study will be the first randomised trial reporting outcomes of low-dose atropine eye-drops for children with myopia in a UK population. Trial registration number: ISRCTN99883695, NCT03690089.

Publication DOI: https://doi.org/10.1136/bjophthalmol-2019-314819
Divisions: Life & Health Sciences > Optometry
Life & Health Sciences > Ophthalmic Research Group
Life & Health Sciences > Vision, Hearing and Language
Life & Health Sciences
Additional Information: © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. Creative Commons Attribution Non-Commercial License
Uncontrolled Keywords: child health (paediatrics),clinical trial,drugs,optics and refraction,treatment medical,Ophthalmology,Sensory Systems,Cellular and Molecular Neuroscience
Full Text Link: http://www.isrc ... /ISRCTN99883695
Related URLs: https://bjo.bmj ... mol-2019-314819 (Publisher URL)
http://www.scop ... tnerID=8YFLogxK (Scopus URL)
PURE Output Type: Article
Published Date: 2019-10-25
Published Online Date: 2019-10-25
Accepted Date: 2019-10-05
Authors: Azuara-Blanco, Augusto
Logan, Nicola ( 0000-0002-0538-9516)
Strang, Niall
Saunders, Kathryn
Allen, Peter M
Weir, Ruth
Doherty, Paul
Adams, Catherine
Gardner, Evie
Hogg, Ruth
McFarland, Margaret
Preston, Jennifer
Verghis, Rejina
Loughman, James J
Flitcroft, Ian
Mackey, David A
Lee, Samantha Sze-Yee
Hammond, Christopher
Congdon, Nathan
Clarke, Mike

Download

Export / Share Citation


Statistics

Additional statistics for this record